https://www.selleckchem.com/pr....oducts/daratumumab.h
Several new classes of glucose-lowering medications have been introduced in the past two decades. Some, such as sodium-glucose cotransporter 2 inhibitors (SGLT2s), have evidence of improved cardiovascular outcomes, while others, such as dipeptidyl peptidase-4 inhibitors (DPP4s), do not. It is therefore important to identify their uptake in order to find ways to support the use of more effective treatments. To analyse the uptake of these new classes among patients with type 2 diabetes. This was a retrospective repeated cross-sectiona
Like
Comment
Share
